Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G. Orlandi P, et al. Among authors: bocci g. Br J Cancer. 2013 Aug 20;109(4):957-64. doi: 10.1038/bjc.2013.398. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860526 Free PMC article.
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G. Derosa L, et al. Among authors: bocci g. Cancer. 2014 Dec 15;120(24):3923-31. doi: 10.1002/cncr.28953. Epub 2014 Aug 8. Cancer. 2014. PMID: 25111199 Free article. Clinical Trial.
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.
Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F. Bouche G, et al. Among authors: bocci g. Ecancermedicalscience. 2014 Sep 9;8:463. doi: 10.3332/ecancer.2014.463. eCollection 2014. Ecancermedicalscience. 2014. PMID: 25228919 Free PMC article.
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G. Allegrini G, et al. Among authors: bocci g. Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140. Pharmacogenomics. 2014. PMID: 25521357 Clinical Trial.
Metronomic chemotherapy for triple negative breast cancer?
Di Desidero T, Kerbel RS, Bocci G. Di Desidero T, et al. Among authors: bocci g. Aging (Albany NY). 2016 Apr;8(4):573-4. doi: 10.18632/aging.100947. Aging (Albany NY). 2016. PMID: 27084985 Free PMC article. No abstract available.
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G. Di Desidero T, et al. Among authors: bocci g. Invest New Drugs. 2016 Dec;34(6):760-770. doi: 10.1007/s10637-016-0385-0. Epub 2016 Aug 24. Invest New Drugs. 2016. PMID: 27557783 Clinical Trial.
237 results